22nd Jul 2019 17:19
(Alliance News) - GlaxoSmithKline PLC on Monday said its ViiV Healthcare has seen positive results from the phase three Brighte study of investigational fostemsavir in heavily treatment-experienced adults with HIV-1.
ViiV is specialist HIV company majority owned by Glaxo, with Pfizer Inc and Shionogi Ltd shareholders.
Brighte is a two-cohort, randomised and non-randomised, phase III clinical trial evaluating the safety and efficacy of fostemsavir.
In the randomised cohort of the study, rates of virologic suppression and immunologic response increased from week 48 to week 96 in this "difficult-to-treat population" with multidrug resistant HIV-1, Glaxo said.
ViiV plans to commence the submission of regulatory applications for fostemsavir, with the US New Drug Application, later this year.
Shares in Glaxo closed up 0.4% at 1,653.03 pence in London on Monday.
Related Shares:
Glaxosmithkline